Are you looking for an exciting new career opportunity in the AI drug discovery space?
Invenia Group has partnered with a Series A biotechnology company aiming to revolutionize the discovery and development of protein therapeutics through novel measurement and design technologies. They have developed a platform that combines NGS & Proteomics to create a pipeline of engineered proteins to create protein therapeutics. The platform is a Multiplex protein quantification (Multiplex in vivo screening of antibody drugs) platform with an NGS sequencing readout element providing unprecedented scale and sensitivity. They combine this with protein engineering and computation design to create antibody-like drugs.
They are currently looking to hire hybrid senior computational/synthetic biologists to join the team.
They’ve only had one person leave the company within the last 3 years which showcases the strength of their workplace culture and values they have in place.
Role responsibilities:
If successful, you will apply statistical methods and machine learning to NGS data to identify novel variants. Develop novel protein engineering platform technologies. Predict sequence-function relationships (e.g. using ML/biophysical models).
What we are looking for:
Sound interesting? To find out more information regarding this opportunity, please apply.